IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11642329 B1

PDFFull Text
Date of Patent:
May. 09, 2023

Filed:

Jun. 23, 2022

Amorphous solid form of compounds containing s—n-valeryl-n- {[2'-( 1 h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations

Applicant:

Novartis Pharmaceuticals Corporation, East Hanover, NJ (US);

Inventors:

Lili Feng, Pine Brook, NJ (US);

Sven Erik Godtfredsen, Chatham, NJ (US);

Paul Allen Sutton, Getzville, NY (US);

Mahavir Prashad, Montville, NJ (US);

Michael J. Girgis, Montville, NJ (US);

Bin Hu, Green Brook, NJ (US);

Yugang Liu, Warren, NJ (US);

Thomas J. Blacklock, East Hanover, NJ (US);

Piotr Henryk Karpinski, Lincoln Park, NJ (US);

Assignee:

Novartis Pharmaceuticals Corporation, East Hanover, NJ (US);

Attorney:

Timothy P. O'Dea

Primary Examiner:

Timothy P Thomas

Int. Cl.
CPC ...
A61K 31/216 (2006.01); A61K 31/41 (2006.01); C07C 233/47 (2006.01); C07D 257/04 (2006.01); A61K 45/06 (2006.01); A61K 31/4422 (2006.01); A61K 31/5415 (2006.01); C07D 207/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/216 (2013.01); A61K 31/41 (2013.01); A61K 31/4422 (2013.01); A61K 31/5415 (2013.01); A61K 45/06 (2013.01); C07C 233/47 (2013.01); C07D 207/50 (2013.01); C07D 257/04 (2013.01); A61K 2300/00 (2013.01);
Abstract

An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.

Find Patent Forward Citations

Loading…